Bristol Myers Squibb (CELG-RI) Dividend Coverage Ratio (QoQ) (2009 - 2026)
Powered by 
Analysis
Bristol Myers Squibb (CELG-RI) Dividend Coverage Ratio (QoQ) (2009 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.84 Bn | 621.08 Bn | 17.26 Bn |
| 2 | AbbVie | 446.83 Bn | 440.26 Bn | 12.70 Bn |
| 3 | Merck | 357.75 Bn | 350.61 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.56 Bn | 259.87 Bn | 11.24 Bn |
| 5 | Pfizer | 156.74 Bn | 145.04 Bn | 10.94 Bn |
| 6 | Sanofi | 52.18 Bn | 44.80 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.15 Bn | 43.15 Bn | - |
| 8 | Incyte | 24.65 Bn | 20.11 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.30 Bn | 18.63 Bn | 683.80 Mn |
| 10 | Bristol Myers Squibb | 232.18 Mn | -10.83 Bn | 9.25 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 23.39% |
| Mar 31, 2026 | 142.65% |
| Dec 31, 2025 | -50.48% |
| Sep 30, 2025 | 67.04% |
| Jun 30, 2025 | -46.84% |
| Mar 31, 2025 | 3,036.47% |
| Dec 31, 2024 | -93.76% |
| Sep 30, 2024 | -27.79% |
| Jun 30, 2024 | 114.08% |
| Mar 31, 2024 | -746.83% |
| Dec 31, 2023 | -6.46% |
| Sep 30, 2023 | -6.42% |
| Jun 30, 2023 | -8.46% |
| Mar 31, 2023 | 7.18% |
| Dec 31, 2022 | 26.92% |
| Sep 30, 2022 | -98.83% |
| Jun 30, 2022 | 10,898.73% |
| Mar 31, 2022 | -49.84% |
| Dec 31, 2021 | 51.58% |
| Sep 30, 2021 | -98.93% |